MYO6 is highly expressed in prostate cancer, ovarian cancer, gastric cancer and oral squamous cell carcinoma and can promote proliferation and migration through the lncRNA UCA1/miR-143/MYO6 axis (29–32). Here, UCA1 is linked to prostate carcinoma.